ClinicalTrials.gg
RecruitingNCT06945081WILDERMEUpdated Jan 23, 2026

Wilson's Disease Treated With D-Penicillamine: Characterization of Skin Damage Secondary to Treatment by Measuring Skin Elasticity

An interventional study of Preparation of forearm molds with SILFLO® silicone in Wilson Disease, D-Penicillamine and Effect of D-penicilline on Cutaneous Elastity of Wilson's Patient, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Recruiting at 2 sites in France. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Hepatolenticular Degeneration with a site in France — 8 open to participants now, 8 under way, none of them phase 3. Hepatolenticular Degeneration · France.

Planned enrollment
4th of 11
120 · median 40
Started
2025
with 1 other
No phase
8 of 17
3 open now
Registered
16th of 17
by date
Lead sponsor
1 of 17
Centre Hospitalier Universitaire de Saint Etienne

Among the 17 studies in Hepatolenticular Degeneration with a site in France, this one is the 4th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2025, is one of 8 with no phase, and was the 16th registered.

Hepatolenticular Degeneration

80 studies on the registry are indexed under Hepatolenticular Degeneration; 31 are open to participants now.

Browse Hepatolenticular Degeneration studies →

Open to participants now

8 of the 17 studies in Hepatolenticular Degeneration with a site in France are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 22 Hepatolenticular Degeneration studies recruiting now, 17 (77%) set no upper age limit and 4 (18%) stop at 75 or younger; 14 take children under 18; 3 take healthy volunteers.

This study: 12 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Hepatolenticular Degeneration with a site in France, or all of them as a file.
02

Study summary

Wilson's disease is a genetic disorder, resulting from an anomaly present on the ATP7B gene located on chromosome 13, causing a progressive accumulation of copper in various organs such as the liver, nervous system and cornea, leading to various hepatic and neurological disorders and a systemic evolution.

Currently, the first-line treatment for this disease is D-Penicillamine, which acts by chelation and promotes copper excretion through the urine. Unfortunately, this treatment also has significant side-effects, particularly on the skin. However, the pathogenesis of elastopathy in patients with Wilson's disease has yet to be fully characterized, and needs to be better understood in order to adapt the therapeutic strategy.

A silicon mold will be made on Wilson's disease patients, enabling the skin micro-relief to be shaped, and analyzed by confocal laser in comparison with the skin of healthy volunteers.

03

Conditions studied

  • Wilson Disease
  • D-Penicillamine
  • Effect of D-penicilline on Cutaneous Elastity of Wilson's Patient

Keywords

  • Cutaneous elastopathy
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Diseased patients :

  • Patient over 12 years old
  • Patient with Wilson's disease confirmed by genetic analysis
  • Patient followed up in the Wilson's Disease Reference Center for his care
  • Patient treated with D-Penicillamine
  • Patient with no other known elastic tissue pathology

Healthy volunteers :

  • Patient over 12 years old
  • Patient followed up in the dermatology department of St Etienne University Hospital
  • Patient matched on sex and age with a patient from the "Wilson's disease" group
  • Patient with no elastic tissue pathology

All patients :

  • Patient affiliated to a national social security
  • Patient with written

Exclusion criteria

Exclusion Criteria:

All patients:

  • Patient not taking a treatment (at investigator's discretion) that may modify skin elasticity
  • Patient with pathological lesion(s) on forearm or cheek
  • Patient with a potentially active/rejuvenative forearm or cheek treatment
  • Patient having applied cream and/or make-up to the areas to be molded (forearm and cheek)
  • Patient under guardianship
  • Patient unable to follow study procedures
  • Pregnant or breast-feeding women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    D-penicillamine

    Patients with Wilson's disease treated with D-penicillamine for various exposure times

    Other: Preparation of forearm molds with SILFLO® silicone

  • Active comparator
    Healthy patients

    Patients not diagnosed with wilson's disease and not receiving treatment that may affect skin elasticity

    Other: Preparation of forearm molds with SILFLO® silicone

Interventions

  • OtherPreparation of forearm molds with SILFLO® silicone

    Preparation of forearm molds with SILFLO® silicone (MONADERM, Monaco), CE-marked and already used routinely in dermocosmetics. These molds will, then, be analyzed.

06

What researchers measure

Primary outcomes

  1. Skin tension measurement

    Measurement of skin tension indices on a silicone cast of the inner forearm with a confocal laser expressed as a percentage (from 0 (perfect tension balance) to 100 (absolute imbalance on one tension axis)) of patients treated with D-Penicillamine and healthy patients.

    Time frame: At inclusion

Secondary outcomes

  1. Skin tension indices measurement on silicone casts

    Measurement of skin tension indices on silicone casts of the inner and outer forearm with confocal laser and comparison between different groups of patients according to duration of exposure to treatment in subgroups: (\< to 5 years, 5 to 10 years, 10 to 15 years and 15 years and more).

    Time frame: Year 1

  2. Skin tension indice measurement with confocal laser

    Measurement of skin tension indices on various silicone casts of the inner and outer forearm and cheek with confocal laser and comparison between patients and age- and sex-matched control group patients

    Time frame: Year 1

07

Study locations

1 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Jun 2026, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2025
First posted
Apr 25, 2025
StartActual
Nov 28, 2025
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2026
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06945081
Responsible party
Sponsor
First posted
Apr 25, 2025
Start date
Nov 28, 2025
Primary completion
Jun 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Jan 23, 2026

Study contacts

Jean Luc PERROT, PHD
Contact
j.luc.perrot@chu-st-etienne.fr
(0)4 77 82 83 33 ext. +33
Eduardo COUCHONNAL-BEDOYA, MD
Contact
(0)4 72 35 70 50 ext. +33
JEAN-LUC PERROT, PHD
principal investigator · Service de Dermatologie, Hôpital Nord CHU de Saint-Étienne 42055 SAINT-ETIENNE Cedex 2

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion